https://en.wikipedia.org/wiki/Pfizer%E2%80%93BioNTech_COVID-19_vaccine
BioNTech received a US$135 million investment from Fosun in March 2020, in exchange for 1.58 million shares in BioNTech and the future development and marketing rights of BNT162b2 in China.[46][21]
In April 2020, BioNTech signed a partnership with Pfizer and received $185 million, including an equity investment of approximately $113 million.[59][60]
The BioNTech technology for the BNT162b2 vaccine is based on use of nucleoside-modified mRNA (modRNA) which encodes part of the spike protein found on the surface of the SARS-CoV-2 virus, triggering an immune response against infection by the virus protein.[76]
The vaccine candidate BNT162b2 was chosen as the most promising among three others with similar technology developed by BioNTech.[28][76][65] Before choosing BNT162b2, BioNTech and Pfizer had conducted Phase I trials on BNT162b1 in Germany and the United States, while Fosun performed a Phase I trial in China.[27][77] In these Phase I studies, BNT162b2 was shown to have a better safety profile than the other three BioNTech candidates.[77]